{"paper_id": "3e7cf935ad3536657fb01ff5d1460f6a94c34790", "metadata": {"title": "Accepted Article The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19", "authors": [{"first": "Wei", "middle": [], "last": "Zhou", "suffix": "", "affiliation": {"laboratory": "", "institution": "Chinese Academy of Medical Sciences", "location": {"postCode": "100730", "settlement": "Beijing", "country": "P.R. China"}}, "email": ""}, {"first": "Xiaomao", "middle": [], "last": "Xu", "suffix": "", "affiliation": {"laboratory": "", "institution": "Chinese Academy of Medical Sciences", "location": {"postCode": "100730", "settlement": "Beijing", "country": "P.R. China"}}, "email": ""}, {"first": "Zhigang", "middle": [], "last": "Chang", "suffix": "", "affiliation": {"laboratory": "", "institution": "Chinese Academy of Medical Sciences", "location": {"postCode": "100730", "settlement": "Beijing", "country": "P.R. China"}}, "email": ""}, {"first": "He", "middle": [], "last": "Wang", "suffix": "", "affiliation": {"laboratory": "", "institution": "Chinese Academy of Medical Sciences", "location": {"postCode": "100730", "settlement": "Beijing", "country": "P.R. China"}}, "email": ""}, {"first": "Xuefeng", "middle": [], "last": "Zhong", "suffix": "", "affiliation": {"laboratory": "", "institution": "Chinese Academy of Medical Sciences", "location": {"postCode": "100730", "settlement": "Beijing", "country": "P.R. China"}}, "email": ""}, {"first": "Xunliang", "middle": [], "last": "Tong", "suffix": "", "affiliation": {"laboratory": "", "institution": "Chinese Academy of Medical Sciences", "location": {"postCode": "100730", "settlement": "Beijing", "country": "P.R. China"}}, "email": ""}, {"first": "Taotao", "middle": [], "last": "Liu", "suffix": "", "affiliation": {"laboratory": "", "institution": "Chinese Academy of Medical Sciences", "location": {"postCode": "100730", "settlement": "Beijing", "country": "P.R. China"}}, "email": ""}, {"first": "Yanming", "middle": [], "last": "Li", "suffix": "", "affiliation": {"laboratory": "", "institution": "Chinese Academy of Medical Sciences", "location": {"postCode": "100730", "settlement": "Beijing", "country": "P.R. China"}}, "email": ""}, {"first": "", "middle": ["#"], "last": "", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [{"text": "Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a worldwide pandemic since it emerged in December, 2019. Previous studies have reported rapid antibody response to SARS-CoV-2 with the first 2-3 weeks after symptom onset. Here, we retrospectively described the dynamic changes of serum IgM and IgG specifically against SARS-CoV-2 in later weeks (mainly 4-10 weeks) in 97 hospitalized patients with COVID-19. We observed that serum IgM and IgG, especially in patients with moderate-to-high levels, declined significantly between week 4-10 after illness onset. Notably, IgG levels in high percentage of patients (77.5%, 31/40) rapidly declined by half, from 212.5 (range, 163.7-420.3) to 96.3 (range, 75.0-133.4) AU/ml, within 1-2 weeks in the second month and then sustained around 100 AU/ml until discharge from hospital. Significant reduction of IgM was also observed as SARS-CoV-2 nucleic acid converted to negative (p=0.002).", "cite_spans": [], "ref_spans": [], "section": "Abstract"}, {"text": "In the recovery stage, serum IgG declined significantly (early vs. late recovery stage, n=16, p=0.003) with a median reduction of 50.0% (range, 3.7-77.0%). Our results suggested the decline of IgM may be an indicator of virus clearance and recovery patients may have robust immunity against reinfection within at least 3 months after illness onset. Yet, the rapid reduction of IgG by half arises serious concerns on the robustness and sustainability of humoral immune response in the future period after discharge, which is crucial for immunity strategy and developing vaccine.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "Coronavirus disease 2019 (COVID- 19) , an acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China on December 12, 2019 and became a worldwide pandemic in 2020 1, 2 . Accumulatively, nearly 10 million confirmed COVID-19 cases and 500 thousand deaths have been reported around the world by June 27, 2020 according to World Health Organization (WHO). Most of the patients had typically clinical symptoms including fever, cough, fatigue and dyspnea which appeared 2-14 days after exposure 2, 3 . About 20% patients may progress to a severe or critical disease with a higher mortality rate than mild cases 3 .", "cite_spans": [{"start": 33, "end": 36, "text": "19)", "ref_id": "BIBREF21"}, {"start": 238, "end": 240, "text": "1,", "ref_id": "BIBREF0"}, {"start": 241, "end": 242, "text": "2", "ref_id": "BIBREF1"}, {"start": 564, "end": 566, "text": "2,", "ref_id": "BIBREF1"}, {"start": 567, "end": 568, "text": "3", "ref_id": "BIBREF2"}], "ref_spans": [], "section": "Introduction"}, {"text": "patients also have antibody response to virus infection [4] [5] [6] . Serum IgM and IgG against SARS-CoV-2 were detectable within the first several weeks after symptom onset 4, [7] [8] [9] . They were detectable as early as 4 days and reached a peak in the second week after onset 7, 8 . Almost all the infected cases had seropositive antibodies in the first 3 weeks post illness onset 4 . Thus, the serological testing for specific antibodies against SARS-CoV-2 in early stage may be helpful for the diagnosis of suspected cases in the context of high false-negative risk of RT-PCR assay in detecting virus nucleic acid 8, 10 . Serologic testing in conjunction with RT-PCR have been demonstrated to enhance the sensitivity of detecting symptomatic or asymptomatic individuals infected with SARS-CoV-2 11 .", "cite_spans": [{"start": 56, "end": 59, "text": "[4]", "ref_id": "BIBREF3"}, {"start": 60, "end": 63, "text": "[5]", "ref_id": null}, {"start": 64, "end": 67, "text": "[6]", "ref_id": "BIBREF6"}, {"start": 174, "end": 176, "text": "4,", "ref_id": "BIBREF3"}, {"start": 177, "end": 180, "text": "[7]", "ref_id": "BIBREF7"}, {"start": 181, "end": 184, "text": "[8]", "ref_id": "BIBREF8"}, {"start": 185, "end": 188, "text": "[9]", "ref_id": "BIBREF9"}, {"start": 281, "end": 283, "text": "7,", "ref_id": "BIBREF7"}, {"start": 284, "end": 285, "text": "8", "ref_id": "BIBREF8"}, {"start": 386, "end": 387, "text": "4", "ref_id": "BIBREF3"}, {"start": 621, "end": 623, "text": "8,", "ref_id": "BIBREF8"}, {"start": 624, "end": 626, "text": "10", "ref_id": "BIBREF11"}, {"start": 802, "end": 804, "text": "11", "ref_id": "BIBREF12"}], "ref_spans": [], "section": "Similar to patients infected by SARS-CoV or MERS-CoV, COVID-19"}, {"text": "However, most of previous publications have only focused on the acute response phase within 2~3 weeks after onset in COVID-19. Our study aims to describe the dynamic changes of serum antibody against SARS-CoV-2 in the later weeks after onset, especially when the virus nucleic acid converts to negative and when patients are recovering from the disease. This article is protected by copyright. All rights reserved. Recovery was defined as SARS-CoV-2 nucleic acid conversion negative. To avoid false negative, only the patients with negative results in all of the subsequent nucleic acid tests after conversion were confirmed to be truly recovered. We defined early recovery stage (ERS) as the first 7 days and late recovery stage (LRS) as more than 14 days after the first recovery date 12 .", "cite_spans": [], "ref_spans": [], "section": "Similar to patients infected by SARS-CoV or MERS-CoV, COVID-19"}, {"text": "The serum antibodies against SARS-CoV-2 (IgM and IgG) was detected by enzyme linked immunosorbent assay (iFlash 2019-nCoV IgM and IgG kits from YHLO Biotech Co., Ltd, Shenzhen, China) using iFlash3000 Chemiluminescence Immunoassay Analyzer (YHLO Biotech Co., Ltd, Shenzhen, China).", "cite_spans": [], "ref_spans": [], "section": "Patients and data collection"}, {"text": "Continuous variables were present as median and interquartile range (IQR).", "cite_spans": [], "ref_spans": [], "section": "Statistical analysis"}, {"text": "Independent continuous variables were compared using Mann-Whitney U test and paired variables with Wilcoxon signed-rank sum test. Categorical variables were present as number and percentage, and compared using \u03c7 2 test or Fisher's exact test as appropriate. P value < 0.05 was considered statistically significant. All statistical analyses and scientific graphics were made by using GraphPad Prism 8.0 (GraphPad Software, Inc., CA. USA).", "cite_spans": [], "ref_spans": [], "section": "Statistical analysis"}, {"text": "After excluding 10 patients who only received antibody tests prior to 3 weeks after illness onset, a total of 97 COVID-19 patients (62 severe and 35 non-severe) were included in our study ( Table 1 ). The median age was 65 years (IQR, 53-72), and severe patients were older than non-severe patients (p=0.007). Male and current smokers were at higher risk of being severely ill (p=0.022 and 0.003, respectively). Cough, fatigue, dyspnea and fever were the most common Accepted Article symptoms, which were reported in 86.6, 71.1, 68.0 and 59.8% of all patients.", "cite_spans": [], "ref_spans": [{"start": 190, "end": 197, "text": "Table 1", "ref_id": "TABREF1"}], "section": "Baseline descriptions"}, {"text": "Fever, dyspnea, myalgia and fatigue were more frequently manifested in severe patients (all p<0.01). No significant differences of comorbidities except malignancy were observed between severe and non-severe patients.", "cite_spans": [], "ref_spans": [], "section": "Baseline descriptions"}, {"text": "All patients were discharged from hospital before April 8, 2020, except one critical patient who died from acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) 33 days after symptom onset.", "cite_spans": [], "ref_spans": [], "section": "Baseline descriptions"}, {"text": "Severe patients had shorter duration from symptom onset to admission to hospital (median 9.0 vs. 14.0 days, p=0.001) but longer duration of hospitalization (median 45.0 vs. 32.0 days, p<0.001). The median time for SARS-CoV-2 nucleic acid transferring negative was 34.0 days with no significant difference between severe and non-severe groups.", "cite_spans": [], "ref_spans": [], "section": "Baseline descriptions"}, {"text": "We illustrated the overall profile of serum IgM and IgG against SARS-CoV-2 from week 4 to 10 after illness onset in Figure Median serum IgG was detected as high as more than 150 AU/ml in week 4-6 but markedly reduced to nearly 100 AU/ml which plateaued during week 7-10 ( Figure   1b ).", "cite_spans": [], "ref_spans": [{"start": 116, "end": 122, "text": "Figure", "ref_id": null}, {"start": 272, "end": 283, "text": "Figure   1b", "ref_id": "FIGREF0"}], "section": "Levels of serum antibodies at different weeks"}, {"text": "When stratifying patients according to severity, we found the antibody profile of serum IgM and IgG in severe and non-severe patients were similar to that of the total sample. In addition, the difference of antibody levels between This article is protected by copyright. All rights reserved.", "cite_spans": [], "ref_spans": [], "section": "Levels of serum antibodies at different weeks"}, {"text": "severe and non-severe groups was not statistically significant, although non-severe patients had slightly lower median antibody levels in some weeks (Table 2) , which may be due to small sample size. No difference was observed between male and female.", "cite_spans": [], "ref_spans": [{"start": 149, "end": 158, "text": "(Table 2)", "ref_id": null}], "section": "Accepted Article"}, {"text": "Since the immune response may differ greatly among individuals, the change pattern of serum antibodies revealed by analyzing unpaired date may be biased.", "cite_spans": [], "ref_spans": [], "section": "Changes of serum antibodies using paired data"}, {"text": "To investigate the change pattern more precisely, we extracted paired data from patients who had antibody tests in at least two consecutive weeks and compared the serum antibody levels between consecutive weeks using Wilcoxon AU/ml (p<0.001) while IgG was not obviously altered. In the other week pairs, the antibody levels had no obvious change.", "cite_spans": [], "ref_spans": [], "section": "Changes of serum antibodies using paired data"}, {"text": "Dynamic of serum antibody levels of 40 patients who received antibody tests in at least 3 weeks among week 4-9 after illness onset were shown in Figure 3 . In addition, the changes of antibody levels of each patients were shown in Figure 4 .", "cite_spans": [], "ref_spans": [{"start": 145, "end": 153, "text": "Figure 3", "ref_id": null}, {"start": 231, "end": 239, "text": "Figure 4", "ref_id": null}], "section": "Rapid reduction of serum IgG"}, {"text": "We stratified patients according to antibody level of the first antibody test.", "cite_spans": [], "ref_spans": [], "section": "Rapid reduction of serum IgG"}, {"text": "Patients in low-IgM group (<20 AU/ml, n=12) had persistently low IgM levels in week 4-9 without obvious changes (Figure 3a, 4a) . Meanwhile, serum IgM of patients in moderate-IgM group (20~100 AU/ml, n=19) gradually declined (Figure 3b, 4b) and IgM of patients in high-IgM group (>100 AU/ml, n=9) had significant reduction of more than 50AU/ml in week 4-9 (Figure 3c, 4c) .", "cite_spans": [], "ref_spans": [{"start": 112, "end": 127, "text": "(Figure 3a, 4a)", "ref_id": null}, {"start": 225, "end": 240, "text": "(Figure 3b, 4b)", "ref_id": null}, {"start": 356, "end": 371, "text": "(Figure 3c, 4c)", "ref_id": null}], "section": "Rapid reduction of serum IgG"}, {"text": "Serum IgG of most patients in low-IgG group (<100 AU/ml, n=7) also sustained at low level (Figure 3d, 4d) . In moderate-IgG group (100~200 AU/ml, n=15), serum IgG of 7 patients increased firstly to a peak and then rapidly declined, while the others declined directly (Figure 3e, 4e) . In high-IgG group (>200 AU/ml, n=18), most patients had great reduction of >100 AU/ml in IgG (Figure 3f, 4f) . However, serum IgG in moderate and high groups sustained around 100 AU/ml after significant reduction until discharge from hospital.", "cite_spans": [], "ref_spans": [{"start": 90, "end": 105, "text": "(Figure 3d, 4d)", "ref_id": null}, {"start": 267, "end": 282, "text": "(Figure 3e, 4e)", "ref_id": null}, {"start": 378, "end": 393, "text": "(Figure 3f, 4f)", "ref_id": null}], "section": "Rapid reduction of serum IgG"}, {"text": "Notably, serum IgG in 60.0% (24/40) of patients rapidly declined within 1", "cite_spans": [], "ref_spans": [], "section": "Rapid reduction of serum IgG"}, {"text": "week and 17.5% (7/40) within 2 weeks (no antibody tests in the intermediate week) and then sustained until discharge. The median levels of serum IgG before and after rapid decline were 212.5 (range, 163.7-420.3) and 96.3 (range, 75.0-133.4) AU/ml, respectively, and the median reduction was 52.7% (range, 39.8-75.2%). Therefore, it was reasonable to infer that most patients had a sudden reduction of IgG by half within 1 week in the second month after illness onset.", "cite_spans": [], "ref_spans": [], "section": "Rapid reduction of serum IgG"}, {"text": "In the rest of the patients, we found 4 patients with low IgG levels (<100AU/ml) also had sharp reduction of IgG by half (range, 45.5-60.4%) within 1-2 weeks.", "cite_spans": [], "ref_spans": [], "section": "Rapid reduction of serum IgG"}, {"text": "We analyzed paired data from 18 patients who had antibody tests in acute stage (AS, the period when the SARS-CoV-2 nucleic acid can be found in respiratory specimen) and ERS to investigate the changes of serum antibodies This article is protected by copyright. All rights reserved.", "cite_spans": [], "ref_spans": [], "section": "Antibody changes as the nucleic acid transferring negative"}, {"text": "with the nucleic acid conversion negative (i.e., recovery). The median days of transferring negative after illness onset in these patients were 46.0 (IQR, 36.8-50.8). If a patient had multiple antibody data in AS, only the last one was used. IgM level significantly decreased (AS: 28.2 (IQR, 8.7-230); ERS: 16.0 (IQR, 6.5-32.6); p=0.002) as the viral RNA turned negative (Figure 5a ). IgG level decreased from 133.0 (IQR, 81.9-209.9) to 96.4 (IQR, 87.1-118.4) AU/ml but the difference did not reach statistical significance (p=0.108, Figure 5b ). ", "cite_spans": [], "ref_spans": [{"start": 371, "end": 381, "text": "(Figure 5a", "ref_id": null}, {"start": 534, "end": 543, "text": "Figure 5b", "ref_id": null}], "section": "Accepted Article"}, {"text": "The current study described the dynamic changes of serum IgM and IgG against SARS-CoV-2 after 3 weeks following illness onset in hospitalized patients with COVID-19. In overall, IgM and IgG declined in the second month after illness onset, especially in patients with moderate-to-high levels of serum antibodies that represented a stronger antibody response to SARS-CoV-2.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "Antibody response is critical for virus clearance and preventing reinfection.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "Previous studies have reported rapid production of specific IgM and IgG to SARS-CoV-2 within the first week and peak level of antibodies by 2-3 weeks after disease onset 4, 10, 13 . The peak of antibodies may not persist for long-time duration. We found the decline of serum IgM after peak mainly occurred in the This article is protected by copyright. All rights reserved.", "cite_spans": [], "ref_spans": [], "section": "Discussion"}, {"text": "second month (week 5-8) after onset. This was parallel to virological assessment results that SARS-CoV-2 nucleic acid of most patients turned negative in week 4-7 (median 34 days, IQR 23.8-44.2) since illness onset. Subsequent paired-data analysis revealed that IgM level significantly declined as virus was completely cleared. Thus, it seems to be conclusive that IgM titer increases rapidly within the first 2 weeks, persists in the following 1-2 weeks as virus are being cleared, and declines since 4 th week after illness onset as virus nucleic acid turns negative 14 .", "cite_spans": [{"start": 569, "end": 571, "text": "14", "ref_id": "BIBREF15"}], "ref_spans": [], "section": "Accepted Article"}, {"text": "Therefore, the decline of IgM may be an indicator of virus clearance, which may help determine the true nucleic acid conversion negative in conjunction with RT-PCR testing. It could be served as criterion for discharge and ending quarantine, especially for mildly symptomatic or asymptomatic cases.", "cite_spans": [], "ref_spans": [], "section": "Accepted Article"}, {"text": "Sustained IgG level is crucial for shaping memory immune to prevent reinfection. Previous studies revealed detectable antibody levels persisted for more than 2 years in SARS-CoV-and MERS-CoV-infected patients 15, 16 . It is unclear how long specific IgG against SARS-CoV-2 will last. The present study showed a significant reduction of IgG in week 5-7 that only continued for 1-2 weeks but a sustained IgG level since 7 th week after illness onset until discharge.", "cite_spans": [{"start": 209, "end": 212, "text": "15,", "ref_id": "BIBREF16"}, {"start": 213, "end": 215, "text": "16", "ref_id": "BIBREF17"}], "ref_spans": [], "section": "Accepted Article"}, {"text": "The level of IgG decreased from over 150 AU/ml and then plateaued around 100 AU/ml. Serum IgG was still detectable in two patients as long as 11 weeks since illness onset. Analysis using paired data showed that IgG may occur in the process of recovery. Our findings were consistent with previous studies 17, 18 IgG 8 weeks after they were discharged from hospital 17 . Notably, the decline of IgG mainly occurred in patients with moderate-to-high IgG levels, indicating that stronger antibody response did not always necessarily convert to more robust long term humoral immunity against reinfection.", "cite_spans": [{"start": 308, "end": 310, "text": "18", "ref_id": "BIBREF19"}, {"start": 364, "end": 366, "text": "17", "ref_id": "BIBREF18"}], "ref_spans": [], "section": "Accepted Article"}, {"text": "Additionally, dynamic analysis in current study showed that IgG levels in most patients rapidly declined by half within 1-2 weeks in the second month after illness onset. Several patients with IgG levels <100AU/ml also had a rapid reduction by half. This may arise serious concerns that IgG would have logarithmically declined at certain time intervals in the future and recovery patients may become vulnerable to SARS-CoV-2 again. More serological studies investigating the dynamics of antibodies in recovery patients for a longer time period (3 months or more after discharge) are urgent need to determine the duration of humoral immunity, which is pivotal for immunity strategy and developing vaccine.", "cite_spans": [], "ref_spans": [], "section": "Accepted Article"}, {"text": "The immune response to SARS-CoV-2 may differ by disease severity.", "cite_spans": [], "ref_spans": [], "section": "Accepted Article"}, {"text": "Immunological survey demonstrated that critical ill cases had dramatically higher levels of IL-2R, IL-6, IL-10 and TNF-\u03b1 but lower counts of T lymphocytes, CD4 + T cells and CD8 + T cells as compared with moderate cases 19 , so that IL-2R/lymphocyte may be a useful marker for monitoring the progression and predicting the progression 20 . Serological assays also revealed higher titers of IgG 4 and total antibody 10 in severe patients than non-severe patients, which was 10 . Our study revealed that serum IgM and IgG levels in 4 or more weeks after symptom onset were comparable between severe and non-severe patients. Notably, non-severe patients had lower median IgM levels than severe patients in week 4 and 5, but the difference did not reach statistical significance (p=0.850 and 0.052, respectively), which may be due to small sample size.", "cite_spans": [{"start": 220, "end": 222, "text": "19", "ref_id": "BIBREF21"}, {"start": 473, "end": 475, "text": "10", "ref_id": "BIBREF11"}], "ref_spans": [], "section": "Accepted Article"}, {"text": "Therefore, more studies are needed to clarify the precise association between antibody-mediated immune response and disease severity.", "cite_spans": [], "ref_spans": [], "section": "Accepted Article"}, {"text": "Some limitations in our study should be noted. Firstly, this is a retrospective study and serological testing has not become regular until late February, 2020.", "cite_spans": [], "ref_spans": [], "section": "Accepted Article"}, {"text": "Thus, most patients had incomplete weekly data of antibody testing from 4 th week to discharge, and only a small proportion of patients were included in paired analysis. Secondly, we did not discriminate binding antibodies specific to SARS-CoV-2 N and S protein (i.e. N-IgM, N-IgG, S-IgM, S-IgG). Thirdly, the sample size is relatively small with inherently reduced statistical power. Furthermore subgroups analysis stratified by age and comorbidities were not available in our study.", "cite_spans": [], "ref_spans": [], "section": "Accepted Article"}, {"text": "In conclusion, our study described the dynamic changes of serum antibodies of patients with COVID-19 and provided deep insight into the clinical course and humoral immune response to SARS-CoV-2 during month 2-3 after illness onset.", "cite_spans": [], "ref_spans": [], "section": "Accepted Article"}, {"text": "This study was supported by Special Foundation for National Science and This article is protected by copyright. All rights reserved.", "cite_spans": [], "ref_spans": [], "section": "Acknowledgments"}, {"text": "Coronary heart disease 15 ", "cite_spans": [{"start": 23, "end": 25, "text": "15", "ref_id": "BIBREF16"}], "ref_spans": [], "section": "Accepted Article"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "A Novel Coronavirus from Patients with Pneumonia in China", "authors": [{"first": "N", "middle": [], "last": "Zhu", "suffix": ""}, {"first": "D", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "W", "middle": [], "last": "Wang", "suffix": ""}], "year": 2019, "venue": "N Engl J Med", "volume": "382", "issn": "8", "pages": "727--733", "other_ids": {"DOI": ["10.1056/NEJMoa2001017"]}}, "BIBREF1": {"ref_id": "b1", "title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin", "authors": [{"first": "P", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "X", "middle": ["L"], "last": "Yang", "suffix": ""}, {"first": "X", "middle": ["G"], "last": "Wang", "suffix": ""}], "year": 2020, "venue": "Nature", "volume": "579", "issn": "7798", "pages": "270--273", "other_ids": {"DOI": ["10.1038/s41586-020-2012-7"]}}, "BIBREF2": {"ref_id": "b2", "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet", "authors": [{"first": "C", "middle": [], "last": "Huang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "X", "middle": [], "last": "Li", "suffix": ""}], "year": 2020, "venue": "", "volume": "395", "issn": "", "pages": "497--506", "other_ids": {"DOI": ["10.1016/S0140-6736(20)30183-5"]}}, "BIBREF3": {"ref_id": "b3", "title": "Antibody responses to SARS-CoV-2 in patients with COVID-19", "authors": [{"first": "Q", "middle": ["X"], "last": "Long", "suffix": ""}, {"first": "B", "middle": ["Z"], "last": "Liu", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Deng", "suffix": ""}], "year": 2020, "venue": "Nat Med", "volume": "26", "issn": "6", "pages": "845--848", "other_ids": {"DOI": ["10.1038/s41591-020-0897-1"]}}, "BIBREF5": {"ref_id": "b5", "title": "MERS-coronavirus-infected patients according to the disease severity", "authors": [], "year": 2017, "venue": "Diagn Microbiol Infect Dis", "volume": "89", "issn": "2", "pages": "106--111", "other_ids": {"DOI": ["10.1016/j.diagmicrobio.2017.07.006"]}}, "BIBREF6": {"ref_id": "b6", "title": "Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients", "authors": [{"first": "Y", "middle": [], "last": "Shi", "suffix": ""}, {"first": "Z", "middle": [], "last": "Wan", "suffix": ""}, {"first": "L", "middle": [], "last": "Li", "suffix": ""}], "year": 2004, "venue": "J Clin Virol", "volume": "31", "issn": "1", "pages": "66--74", "other_ids": {"DOI": ["10.1016/j.jcv.2004.05.006"]}}, "BIBREF7": {"ref_id": "b7", "title": "Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect", "authors": [{"first": "B", "middle": [], "last": "Sun", "suffix": ""}, {"first": "Y", "middle": [], "last": "Feng", "suffix": ""}, {"first": "X", "middle": [], "last": "Mo", "suffix": ""}], "year": 2020, "venue": "", "volume": "9", "issn": "", "pages": "940--948", "other_ids": {"DOI": ["10.1080/22221751.2020.1762515"]}}, "BIBREF8": {"ref_id": "b8", "title": "Antibody Detection and Dynamic Characteristics in Patients with COVID-19", "authors": [{"first": "F", "middle": [], "last": "Xiang", "suffix": ""}, {"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "X", "middle": [], "last": "He", "suffix": ""}], "year": 2020, "venue": "Clin Infect Dis", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1093/cid/ciaa461"]}}, "BIBREF9": {"ref_id": "b9", "title": "Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients", "authors": [{"first": "Nma", "middle": [], "last": "Okba", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Muller", "suffix": ""}, {"first": "W", "middle": [], "last": "Li", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "Emerg Infect Dis", "authors": [], "year": 2020, "venue": "", "volume": "26", "issn": "", "pages": "1478--1488", "other_ids": {"DOI": ["10.3201/eid2607.200841"]}}, "BIBREF11": {"ref_id": "b11", "title": "Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019", "authors": [{"first": "J", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "Q", "middle": [], "last": "Yuan", "suffix": ""}, {"first": "H", "middle": [], "last": "Wang", "suffix": ""}], "year": 2020, "venue": "Clin Infect Dis", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1093/cid/ciaa344"]}}, "BIBREF12": {"ref_id": "b12", "title": "Review of Current Advances in Serologic Testing for COVID-19", "authors": [{"first": "A", "middle": ["P"], "last": "Espejo", "suffix": ""}, {"first": "Y", "middle": [], "last": "Akgun", "suffix": ""}, {"first": "Al", "middle": [], "last": "Mana", "suffix": ""}, {"first": "A", "middle": ["F"], "last": "", "suffix": ""}], "year": 2020, "venue": "Am J Clin Pathol", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1093/ajcp/aqaa112"]}}, "BIBREF13": {"ref_id": "b13", "title": "Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing", "authors": [{"first": "W", "middle": [], "last": "Wen", "suffix": ""}, {"first": "W", "middle": [], "last": "Su", "suffix": ""}, {"first": "H", "middle": [], "last": "Tang", "suffix": ""}], "year": 2020, "venue": "Cell Discov", "volume": "6", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/s41421-020-0168-9"]}}, "BIBREF14": {"ref_id": "b14", "title": "Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset", "authors": [{"first": "B", "middle": [], "last": "Lou", "suffix": ""}, {"first": "T", "middle": ["D"], "last": "Li", "suffix": ""}, {"first": "S", "middle": ["F"], "last": "Zheng", "suffix": ""}], "year": 2020, "venue": "Eur Respir J", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1183/13993003.00763-2020"]}}, "BIBREF15": {"ref_id": "b15", "title": "A polymeric solid-phase microextraction fiber for the detection of pharmaceuticals in water samples", "authors": [{"first": "Y", "middle": [], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Jie", "suffix": ""}, {"first": "Q", "middle": [], "last": "Hu", "suffix": ""}], "year": 2020, "venue": "J Chromatogr A", "volume": "1623", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.chroma.2020.461171"]}}, "BIBREF16": {"ref_id": "b16", "title": "Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus. Emerg Infect Dis", "authors": [{"first": "D", "middle": ["C"], "last": "Payne", "suffix": ""}, {"first": "I", "middle": [], "last": "Iblan", "suffix": ""}, {"first": "B", "middle": [], "last": "Rha", "suffix": ""}], "year": 2016, "venue": "", "volume": "22", "issn": "", "pages": "1824--1830", "other_ids": {"DOI": ["10.3201/eid2210.160706"]}}, "BIBREF17": {"ref_id": "b17", "title": "Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis", "authors": [{"first": "L", "middle": ["P"], "last": "Wu", "suffix": ""}, {"first": "N", "middle": ["C"], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": ["H"], "last": "Chang", "suffix": ""}], "year": 2007, "venue": "", "volume": "13", "issn": "", "pages": "1562--1566", "other_ids": {"DOI": ["10.3201/eid1310.070576"]}}, "BIBREF18": {"ref_id": "b18", "title": "Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections", "authors": [{"first": "Q", "middle": ["X"], "last": "Long", "suffix": ""}, {"first": "X", "middle": ["J"], "last": "Tang", "suffix": ""}, {"first": "Q", "middle": ["L"], "last": "Shi", "suffix": ""}], "year": 2020, "venue": "Nat Med", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1038/s41591-020-0965-6"]}}, "BIBREF19": {"ref_id": "b19", "title": "Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients", "authors": [{"first": "X", "middle": [], "last": "Wang", "suffix": ""}, {"first": "X", "middle": [], "last": "Guo", "suffix": ""}, {"first": "Q", "middle": [], "last": "Xin", "suffix": ""}], "year": null, "venue": "Clin Infect Dis", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF21": {"ref_id": "b21", "title": "Clinical and immunological features of severe and moderate coronavirus disease 2019", "authors": [{"first": "G", "middle": [], "last": "Chen", "suffix": ""}, {"first": "D", "middle": [], "last": "Wu", "suffix": ""}, {"first": "W", "middle": [], "last": "Guo", "suffix": ""}], "year": 2020, "venue": "J Clin Invest", "volume": "130", "issn": "5", "pages": "2620--2629", "other_ids": {"DOI": ["10.1172/JCI137244"]}}, "BIBREF22": {"ref_id": "b22", "title": "Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19", "authors": [{"first": "H", "middle": [], "last": "Hou", "suffix": ""}, {"first": "B", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "H", "middle": [], "last": "Huang", "suffix": ""}], "year": 2020, "venue": "Clin Exp Immunol", "volume": "201", "issn": "1", "pages": "76--84", "other_ids": {"DOI": ["10.1111/cei.13450"]}}}, "ref_entries": {"FIGREF0": {"text": "The median serum IgM levels from week 4 to 6 were 59.9 (IQR, 27.1-92.2), 37.1 (IQR, 21.7-98.8) and 36.2 (IQR, 12.3-65.3) AU/ml, respectively, which were, however, not significantly different between weeks. The levels in week 7-9 reduced to 22.7 (IQR, 7.4-49.7), 14.6 (IQR, 4.8-37.1) and 8.5 (IQR, 3.8-20.3) AU/ml, respectively, which were significantly lower than those in week 4-6 (all p<0.05).", "latex": null, "type": "figure"}, "FIGREF1": {"text": "IQR, 13.8-54.4) AU/ml ( p=0.032) and IgG from 140.4 (IQR, 89.0-198.7) to 94.6 (IQR, 78.8-166.3) AU/ml (p=0.029). In week 6-7 (n=26), IgM level reduced from 35.5 (IQR, 10.5-58.5) to 17.6 (IQR, 7.3-52.2) AU/ml (p<0.001) and IgG from 147.2 (IQR, 92.9-196) to 95.9 (IQR, 73.6-130.7) AU/ml (p=0.012). In week 7-8 (n=24), IgM level reduced from 39.7 (IQR, 7.4-76.5) to 15.6 (IQR, 4.6-42.6)", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Paired data of antibody levels in ERS and LRS from 16 patients were included to investigate the change pattern in recovery stage of COVID-19 (Figure 6). The median recovery date of these patients was 34.0 (range, 21-44) days after symptom onset. Significant reductions were observed in IgM level (median: 23.6 vs. 10.6, p=0.006) and IgG level (median: 193.7 vs. 101.0, p=0.003) from ERS to LRS. The IgG levels in 87.5% (14/16) of patients decreased in the recovery stage, and the median percentage of reduction was 50.0% (range, 3.7-77.0%).", "latex": null, "type": "figure"}, "FIGREF3": {"text": ". Long et al. observed that IgG levels in recovery patients decreased in 2-3 months upon infection 17 , while Wang et al. reported neutralizing antibodies in half of 8 convalescent patients declined 6-7 weeks after symptom onset 18 . Our study, by using longitudinal data, suggested that IgG level may sustain after the decline for several weeks until at least 3 months after illness onset. This was also supported by Long et al.'s findings that 87.1% of symptomatic patients still had seropositive", "latex": null, "type": "figure"}, "FIGREF4": {"text": "associated with clinical outcomes. This may suggest an effect of antibody-dependent enhancement (ADE). ADE, characterized by enhanced virus entry mediated by antibody and induction of severe inflammatory activation, may contribute to lung injury 21 . It was previously observed in SARS-CoV-1-infected rhesus macaques 22 . However, it is still unclear whether higher IgG titers in critical ill patients contributed to lung pathology in SARS-CoV-2 infection. The divergence of IgG titers between different severity groups was mainly observed in This article is protected by copyright. All rights reserved.", "latex": null, "type": "figure"}, "FIGREF5": {"text": "Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. Feb 21 2019;4(4)doi:10.1172/jci.insight.123158Figure legends", "latex": null, "type": "figure"}, "FIGREF6": {"text": "The levels of antibodies against SARS-CoV-2 in patients in 4-10 weeks after symptom onset. (a) Serum IgM levels. (b) Serum IgG levels. The boxplots show medians and 1 st and 3 rd quartiles, while the whisker show the range. The antibody levels are compared by Mann-Whitney U test. * p<0.05; ** p<0.01; *** p<0.001.", "latex": null, "type": "figure"}, "FIGREF7": {"text": "50.5%) 35 (56.4%) 14 (40.0%) 0.120", "latex": null, "type": "figure"}, "TABREF0": {"text": "This was a retrospective study involving hospitalized patients with confirmed COVID-19 from the Sino-French New City Branch of Tongji Hospital, Wuhan, China from January 26 to March 5, 2020. The medical team from Beijing Hospital had taken full charge of the hospital since late January, 2020. This study was approved by the Ethic Committee of Beijing Hospital, Beijing, China, and informed consent was obtained from the participants. The demographic data, clinical manifestations, chest imaging, comorbid diseases, laboratory findings, treatment and outcomes were obtained from electronic medical records. Since the examination for serum antibody against SARS-CoV-2 were not carried out regularly until late February, 2020, most of the included patients only had series data of serum IgM and IgG between 4 th week after symptom onset and discharge date. The severity of COVID-19 was classified as mild, moderate, severe and critical according to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (version 7) released by the National Health Commission of China (https://ncstatic.clewm.net/rsrc/2020/0311/22/781e459d414bf3f1579bcafef0d80f1 2.pdf). Briefly, confirmed patients meeting any of the following criteria were defined as severe cases: (1) respiratory rate \u2265 30/min; (2) oxygen saturation \u2264 93% at rest; (3) arterial partial pressure of oxygen (PaO 2 )/fraction of inspired oxygen (FiO 2 ) \u2264 300mmHg, or critical cases: (1) respiratory failure and requiring mechanical ventilation (2) shock; (3) with other organ failure that required ICU care. In present study, severe and critical patients were included in the severe group while mild and moderate patients were in the non-severe group.", "latex": null, "type": "table"}, "TABREF1": {"text": "Baseline characteristics of COVID-19 patients", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Variables </td><td>All patients </td><td>Severe patients </td><td>Non-severe </td><td>p </td></tr><tr><td>(n=97) </td><td>(n=62) </td><td>patients (n=35) </td><td>value </td></tr><tr><td>\u00a0</td><td>65.0 </td><td>67.0 </td><td>59.0 </td><td>0.007 </td></tr><tr><td>Apd AAge, years Sex Male Female Current smokeDays from symptom onseadmission viral nucleic acid turning negative dyspnea# Days from admission to discharge Comorbidities </td><td>(53.0-73.0) </td><td>(60.2-74.8) </td><td>(49.0-67.0) </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>0.022 </td></tr><tr><td>51 (52.6%) 46 (47.4%) </td><td>38 (61.3%) 24 (38.7%) </td><td>13 (37.1%) 22 (62.9%) </td><td>\u00a0</td></tr><tr><td>18 (18.6%) </td><td>17 (27.4%) </td><td>1 (2.8%) </td><td>0.003 </td></tr><tr><td>to: </td><td>\u00a0</td><td>14.0 </td><td>\u00a0</td></tr><tr><td>cceterticle rs t \nHypertension </td><td>12.0 (5.0-15.0) </td><td>9.0 (5.0-15.0) </td><td>(10.0-20.5) </td><td>0.001 </td></tr><tr><td>34.0 </td><td>32.0 </td><td>39.0 </td><td>\u00a0</td></tr><tr><td>(23.8-44.2) </td><td>(23.2-42.8) </td><td>(27.7-46.5) </td><td>0.140 </td></tr><tr><td>6.0 (3.0-10.0) </td><td>5.0 (3.0-10.0) </td><td>9.0 (3.5-13.8) </td><td>0.402 </td></tr><tr><td>40.0 </td><td>45.0 </td><td>32.0 </td><td>&lt;0.001 </td></tr><tr><td>(26.0-54.0) </td><td>(35.0-56.0) </td><td>(19.0-41.0) </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>49 (50.5%) </td><td>35 (56.4%) </td><td>14 (40.0%) </td><td>0.120 </td></tr></table></body></html>"}}, "back_matter": [{"text": "The authors declare that there are no conflict of interests.", "cite_spans": [], "ref_spans": [], "section": "Conflict of interests"}, {"text": "YL conceptualized the study. WZ, XX, ZC, HW, XZ, XT and TL collected and analyzed the data. YL and WZ interpreted the data. WZ drafted the manuscript.All authors critically revised the manuscript and approved the final version for publication.", "cite_spans": [], "ref_spans": [], "section": "Author contributions"}, {"text": "The data that support the findings of this study are available from the corresponding author upon reasonable request. ", "cite_spans": [], "ref_spans": [], "section": "Data availability statement:"}]}